Biodel Inc. (Biodel) is a development-stage specialty biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its insulin formulations are designed to be rapid-acting than the formulations are available to Type 1 and Type 2 diabetes patients. It refers to these as ultra-rapid-acting formulations. The clinical trial was a single center, randomized, double-blind, three-period crossover trial in 12 patients with Type 1 diabetes. The Company has conducted Phase 1, Phase 2 and Phase 3 clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin R, which is a branded formulation of RHI, or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.